Lipocine (LPCN)

Lipocine Stock Analysis & Ratings

LPCN Stock Chart & Stats

Day’s Range$0.86 - $0.9056
52-Week Range$0.71 - $1.89
Previous Close$0.87
Average Volume (3M)731.16K
Market Cap$78.34M
P/E Ratio-104.1
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-0.01



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Lipocine’s price range in the past 12 months?
Lipocine lowest stock price was $0.71 and its highest was $1.89 in the past 12 months.
    What is Lipocine’s market cap?
    Lipocine’s market cap is $78.34M.
      What is Lipocine’s price target?
      The average price target for Lipocine is $3.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents 238.91% Increase from the current price of $0.885.
        What do analysts say about Lipocine?
        Lipocine’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Lipocine’s upcoming earnings report date?
          Lipocine’s upcoming earnings report date is Aug 10, 2022 which is in 76 days.
            How were Lipocine’s earnings last quarter?
            Lipocine released its earnings results on May 09, 2022. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.02.
              Is Lipocine overvalued?
              According to Wall Street analysts Lipocine’s price is currently Undervalued.
                Does Lipocine pay dividends?
                Lipocine does not currently pay dividends.
                What is Lipocine’s EPS estimate?
                Lipocine’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Lipocine have?
                Lipocine has 88,500,000 shares outstanding.
                  What happened to Lipocine’s price movement after its last earnings report?
                  Lipocine reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -2.469%.
                    Which hedge fund is a major shareholder of Lipocine?
                    Currently, no hedge funds are holding shares in LPCN


                    Lipocine Stock Analysis

                    The Lipocine stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description


                    Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

                    Similar Stocks
                    Price & Change
                    Seelos Therapeutics
                    Aytu BioScience
                    Eli Lilly & Co
                    Antares Pharma

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis